ArticleMolecular biology of the cell1998
Phosphorothioate antisense oligonucleotides induce the formation of nuclear bodies.
Article in Molecular biology of the cell, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 79 citations in OpenAlex.
- Dysregulation of the DNA damage response by phosphorothioate antisense oligonucleotides.Nature communications · 2026Article
- Unveiling sequence-agnostic mixed-chemical modification patterns for splice-switching oligonucleotides using the NATURA platform.Molecular therapy. Nucleic acids · 2025Article
- Endosomal Escape and Nuclear Localization: Critical Barriers for Therapeutic Nucleic Acids.Molecules (Basel, Switzerland) · 2024Review
- Antisense oligonucleotide development for the selective modulation of CYP3A5 in renal disease.Scientific reports · 2021Article
- High-resolution visualization and quantification of nucleic acid-based therapeutics in cells and tissues using Nanoscale secondary ion mass spectrometry (NanoSIMS).Nucleic acids research · 2021Article
- Recent Advances in the Molecular Beacon Technology for Live-Cell Single-Molecule Imaging.iScience · 2020Review
- Phosphorothioate modified oligonucleotide-protein interactions.Nucleic acids research · 2020Article
- Nusinersen as a Therapeutic Agent for Spinal Muscular Atrophy.Yonsei medical journal · 2020Review
- Understanding the effect of controlling phosphorothioate chirality in the DNA gap on the potency and safety of gapmer antisense oligonucleotides.Nucleic acids research · 2020Article
- Nuclear and Cytoplasmatic Quantification of Unconjugated, Label-Free Locked Nucleic Acid Oligonucleotides.Nucleic acid therapeutics · 2020Article
- Chemical modification of PS-ASO therapeutics reduces cellular protein-binding and improves the therapeutic index.Nature biotechnology · 2019Article
- Nucleic acid binding proteins affect the subcellular distribution of phosphorothioate antisense oligonucleotides.Nucleic acids research · 2017Article
- Engineering Novel Molecular Beacon Constructs to Study Intracellular RNA Dynamics and Localization.Genomics, proteomics & bioinformatics · 2017Review
- Intracellular Distribution and Nuclear Activity of Antisense Oligonucleotides After Unassisted Uptake in Myoblasts and Differentiated Myotubes In Vitro.Nucleic acid therapeutics · 2017Article
- Oligonucleotide therapies for disorders of the nervous system.Nature biotechnology · 2017Article
- Monitoring integrity and localization of modified single-stranded RNA oligonucleotides using ultrasensitive fluorescence methods.PloS one · 2017Article
- Protein Kinase C-α is a Critical Protein for Antisense Oligonucleotide-mediated Silencing in Mammalian Cells.Molecular therapy : the journal of the American Society of Gene Therapy · 2016Article
- A cytoplasmic pathway for gapmer antisense oligonucleotide-mediated gene silencing in mammalian cells.Nucleic acids research · 2015Article
- Therapeutic Oligonucleotides Targeting Liver Disease: TTR Amyloidosis.Molecules (Basel, Switzerland) · 2015Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Antisense oligonucleotides are powerful tools for the in vivo regulation of gene expression. We have characterized the intracellular distribution of fluorescently tagged phosphorothioate oligodeoxynucleotides (PS-ONs) at high resolution under conditions in which PS-ONs have the potential to display antisense activity. Under these conditions PS-ONs predominantly localized to the cell nucleus where they accumulated in 20-30 bright spherical foci designated phosphorothioate bodies (PS bodies), which were set against a diffuse nucleoplasmic population excluding nucleoli. PS bodies are nuclear structures that formed in cells after PS-ON delivery by transfection agents or microinjection but were observed irrespectively of antisense activity or sequence. Ultrastructurally, PS bodies corresponded to electron-dense structures of 150-300 nm diameter and resembled nuclear bodies that were found with lower frequency in cells lacking PS-ONs. The environment of a living cell was required for the de novo formation of PS bodies, which occurred within minutes after the introduction of PS-ONs. PS bodies were stable entities that underwent noticeable reorganization only during mitosis. Upon exit from mitosis, PS bodies were assembled de novo from diffuse PS-ON pools in the daughter nuclei. In situ fractionation demonstrated an association of PS-ONs with the nuclear matrix. Taken together, our data provide evidence for the formation of a nuclear body in cells after introduction of phosphorothioate oligodeoxynucleotides.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.